Accuracy of plasma Aβ40, Aβ42, and p-tau181 to detect CSF Alzheimer’s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform

BACKGROUND: The arrival of new disease-modifying treatments for Alzheimer’s disease (AD) requires the identification of subjects at risk in a simple, inexpensive, and non-invasive way. With tools allowing an adequate screening, it would be possible to optimize the use of these treatments. Plasma mar...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez-Dubarbie, Francisco, Guerra-Ruiz, Armando, López-García, Sara, Lage, Carmen, Fernández-Matarrubia, Marta, Infante, Jon, Pozueta-Cantudo, Ana, García-Martínez, María, Corrales-Pardo, Andrea, Bravo, María, López-Hoyos, Marcos, Irure-Ventura, Juan, Sánchez-Juan, Pascual, García-Unzueta, María Teresa, Rodríguez-Rodríguez, Eloy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544460/
https://www.ncbi.nlm.nih.gov/pubmed/37784138
http://dx.doi.org/10.1186/s13195-023-01319-1

Ejemplares similares

Ejemplares similares